Sanofi is negotiating with American investment fund CD&R to sell its Opella division, which produces Doliprane, France's best-selling medication.

This potential sale has ignited a political storm, with French lawmakers from various parties urging the government to block the transaction.

They argue that the sale threatens national security and undermines France's health sovereignty.

The deal, valued at approximately 16 billion euros, has raised concerns about foreign control over essential health products.

Sanofi plans to retain a 50% stake in Opella for a few years, but the move is seen as a shift towards focusing on innovative drug development.

The French government is seeking assurances to maintain Opella's operations and decision-making within France.